NMRA
What one share of Neumora Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by bringing forward the next generation of novel therapies with brain-penetrant chemistry that offer improved treatment outcomes and quality of life for patients.
Neumora Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.22 |
|---|---|
| Cash and investments | $0.62 |
| Debt | $0.60 |
| Book value | $0.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$4.81 | $0.02 | −$4.24 | — | −$13.70 |
| 2023 | — | −$3.63 | $0.00 | −$2.51 | — | — |
| 2024 | — | −$1.53 | — | −$1.15 | — | $1.78 |
| 2025 | — | −$1.45 | — | −$1.26 | — | $0.60 |